
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz And Grossman, LLC Encourages Shareholders To Seek Compensation For Alleged Wrongdoings
Investigation Details
On August 12, 2024, Syros issued a press release“announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.” According to the Company, the“decision is based on the results of a prespecified interim analysis of the trial,” and its analysis that“the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low.”
What's Next?
If you are aware of any facts relating to this investigation or purchased Syros securities, you can assist this investigation by visiting the firm's site: . You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | ...


Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- The Open Platform Is First Unicorn In Web3 Ecosystem In Telegram At $1Bn Valuation
- Enkrypt Integrates SPACE ID's Payment ID For Seamless CEX Transfers
- Botanix Launches Mainnet To Power The Bitcoin Economy With Chainlink, Fireblocks, GMX, Dolomite And Others
- Trillion Digital Joins The Borderless.Xyz Network, Deepening Institutional-Grade Stablecoin Liquidity
- Yourpropfirm Adds Rithmic Integration For Futures Prop Firms
- BTCC Exchange Reports Remarkable Q2 2025 Performance With $957 Billion Trading Volume
Comments
No comment